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Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal human malignancies. Due 
to the lack of early disease-specific signs and symptoms, early detection of pancreatic cancer 
is really difficult. Detection of preinvasive pancreatic cancer are paramount to improving the 
survival of patients. 
Methods 
In our study, we developed a versatile platform for multimodality imaging of PDAC. The 
system consists of dibenzocyclooctyne (DBCO)-functionalized fucoidan particles (fucoidan-
DBCO), which target a tumor microenvironment biomarker, P-selectin, allows in vivo click 
reaction with azide-functionalized fluorescence dye, gadolinium chelates, iron oxide particles, 
and dextran particles, for fluorescence imaging, T1-weigthed, T2*-weighted MRI and chemical 
exchange saturation transfer (CEST) MRI respectively. The system was applied in a two-step 
manner, where fucoidan-DBCO particles were firstly injected, followed by injection of azide-
functionalized imaging probes.   
We first confirmed the overexpression of P-selectin in a murine PDAC model, derived from 
KrasLSL.G12D/+; P53R172H/+; PdxCretg/+ (KPC) mice, using immunofluorescence staining. We next 
synthesized fucoidan-DBCO, which is reactive to azide-functionalized Cy5.5 fluorescent dye, 
Gd(DOTA), superparamagnetic iron oxide particles (SPIO), and dextran particles through in 
vivo click reaction. We also evaluated the R1, R2 relaxivity of azide-Gd(DOTA) and azide-
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SPIO, and the CEST signal of fucoidan-DBCO and dextran-azide in vitro. Reaction between 
fucoidan-DBCO and azide-Gd(DOTA) was validated by the increase in relaxivity. KPC mice 
were intravenously injected with fucoidan-DBO, followed by injection of azide-Cy5.5 after 1 
hour to test the enhancement of tumor targeting in ex vivo fluorescence imaging. T1-weigthed 
MRI and T1-mapping was also performed in mice with serial injection of fucoidan-DBCO and 
azide-Gd(DOTA). KPC mice without fucoidan-DBCO injection was used as controls. 
Results 
Higher P-selectin expression was observed in KPC tumors than muscles (P=0.001). Mice with 
fucoidan-DBCO injection demonstrated ~50% higher tumor enhancement after injection of 
azide-Cy5.5 in ex vivo fluorescence imaging, compared with control mice (P=0.048, n=3). 
After adding fucoidan-DBCO, the R1 relaxivity of azide-Gd(DOTA) increased from 2.12 mM-
1s-1 to 3.68 mM-1s-1. In MRI, higher tumor enhancement was also observed in mice with serial 
fucoidan-DBCO injection and azide-Gd(DOTA) injection than those with only azide-
Gd(DOTA) injection. 
Conclusions  
We provided a versatile platform for multimodality imaging of PDAC.  
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1. Introduction  
This section introduces the aim of our study: developing a molecular imaging platform of 
PDAC, and the different components of our multimodality imaging platform, which consists 
of fucoidan as the targeting ligand for PDAC, gadolinium-chelates, superparamagnetic iron 
oxide particles and dextran particles, as the imaging moieties. Mechanisms of chemical 
exchange saturation MRI, and T1, T2 agents are introduced.  
1.1 Molecular Imaging of PDAC 
PDAC is one of the most lethal human malignancies, and accounts for 7% of all cancer-related 
deaths in the United States.[1] Due to the lack of early disease-specific signs and symptoms, 
early detection of pancreatic intraepithelial neoplasia (PanIN) lesions and PDAC is difficult 
and only 10-20% of patients with pancreatic cancer are candidates for curative resection.[2] 
Detection of preinvasive pancreatic neoplasms are paramount to improving the survival of 
patients. Compared to biopsy, the current gold standard for PDAC diagnosis, imaging diagnosis 
of PDAC is non-invasive and not prone to errors from limited tissue sampling. However, the 
most commonly used imaging modalities in PDAC, computed tomography (CT) and 
ultrasound, only provide morphological information of the pancreas, which in some cases has 
limited diagnostic value. MRI has a superb soft tissue resolution and is free of ionizing 
radiation. However, current MRI procedures provide no information beyond morphological 
and semi-physiological parameters, such as perfusion, of pancreas, and MRI is only considered 
as secondary “problem-solving” imaging modality in addition to CT and ultrasound.[3, 4] 
2 
 
Molecular imaging provides an opportunity to delineate molecular changes correlated to early 
PDAC tumorigenesis. Tumor vasculature, which is composed of smooth muscle cells, pericytes, 
extracellular matrix, and endothelial cells (ECs), is necessary for the growth and support of 
tumors.[5] Here we aim to develop an MR molecular imaging approach for detecting PDAC 
by the tumor microenvironment (TME). PDAC is a micrometastatic disease and TME plays an 
important role in driving cancer progression.  
1.2 P-selectin as a cancer biomarker 
Selectins are cellular adhesion molecules expressed on the cell surface and assist in cell-cell 
interaction and adhesion. Selectins (E-, P-, L-selectins) were originally named due to the three 
membrane-anchored Ca2+-dependent (C-type) lectins that bind to cell-surface carbohydrate 
ligands and function as adhesion molecules. Their site of expression best classifies the selectins: 
for example, activated endothelium (E-selectin), lymphocytes (L-selectin) and platelets (P-
selectin) [6]. P-selectin is a protein that in humans is encoded by the SELP gene. P-selectin 
functions as a cell adhesion molecule (CAM) on the surfaces of activated endothelial cells, 
which line the inner surface of blood vessels, and activated platelets [7]. P-selectin facilitates 
metastasis by arresting tumor cells at the endothelium. P-selectin is overexpressed on cancer 
cells in many mice and human tumors [5]. Therefore, in this work, P-selectin was chosen as 
the molecular target. It has been previously demonstrated that fucoidan-functionalized 
nanoparticles or microparticles targeted to P-selectin can facilitate the diagnosis of endothelial 
activation and intraluminal thrombosis, and for tumor-targeted drug delivery.[8] The 
nanoparticles targeted the tumor microenvironment to localize chemotherapeutics at tumor 
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sites to achieve targeted specific detection of PDAC tumor. 
1.3 CEST MRI for cancer detection 
Chemical exchange saturation transfer (CEST) is a new and versatile MRI contrast-generating 
mechanism [9], proven to be sensitive to metabolites, extracellular pH, enzymatic activity, and 
gene expression, etc. It has demonstrated in many studies for specifically detecting a wide array 
of labile protons of exchange rate (kex) in the slow to intermediate range (i.e., kex< Δω, where 
Δω is the chemical shift difference between the proton and water in the unit of radian). In brief, 
as illustrated in Figure 1.1, CEST is able to detect the exchangeable protons of the targeted 
agent (solute) through the changes in the NMR signal in water molecule. Without the saturation 
of the targeted proton (such as amide, hydroxide, or bound water group), the NMR proton (1H) 
spectrum shows two peaks for both the solute proton and bulk water proton at different 
resonance frequencies (e.g., 8.25 ppm for amide and 4.75 ppm for bulk water respectively). 
Upon the application of Radiofrequency (RF)[10] saturation pulse irradiating at the offset of 
the exchangeable protons, the NMR signal of those protons will disappear. Over time, as the 
saturated solute protons exchange with bulk water protons to reach equilibrium, not only the 
signal of the solute protons remains saturated, but also a great reduction can be observed on 
the water signal. Plotting the normalized water signal (by its signal in the absence of RF 
saturation pulses) with respect to the offsets of the applied RF saturation pulses gives a so-
called Z-spectrum or CEST spectrum, in which CEST signal can be directly visualized at a 
particular frequency offset Δω defined by the distance between the chemical shift of the solute 
proton and that of bulk water (in ppm). It should be noted that, by MRI convention, the 
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frequency offset is defined as the frequency difference (Δω) between a proton and water, 
whereas the chemical shift of water is set to 0 whereas it is 4.7 ppm by NMR convention [11]. 
The CEST effect can be analyzed and quantified using magnetization transfer ratio asymmetry 
(MTRasym), which will be elaborated in later sections. 
Figure 1.1 Mechanism of CEST from RF Irradiation to Measurement and Analysis. Solute proton 
exchanges RF irradiation with bulk water. 1H spectra are taken before and after saturation equilibrium. 




sensitivity on a per-dextran-unit basis, but detectability on a per-glucose-unit basis is similar to 
those of low-molecular-weight dextrans and glucose. Dextran efficiently facilitates tumor 
receptor detection and assessment of vasculature permeability in CEST MRI. In our study, we 
choose dextran [24], a highly biocompatible diamagnetic CEST agent, as MR molecular 
imaging agent for early detection of PDAC [26]. 
1.5 T1 and T2 MRI agents 
Current commercially available MRI contrast agents are biocompatible magnetic materials that 
alter the longitudinal (T1) and transverse (T2) relaxation rates of the surrounding water protons, 
therefore enhancing image contrast in tissues of interest.[27] MRI contrast agents are generally 
classified as T1 and T2 contrast agents based on their magnetic properties and relaxation 
mechanisms. Gadolinium Gd (III) chelates [28, 29] effectively increase the T1 relaxation rate 
(1/T1) and is often used as T1 contrast agents to produce a positive image contrast. 
Superparamagnetic iron oxide nanoparticles （SPIO）[30] are more effective at increasing T2 
relaxation rate (1/T2) and are commonly used as T2 contrast agents to produce negative image 
contrast. To date, the majority of MRI contrast agents used in clinical practice are Gd (III) 
chelates, with more than 10 million contrast enhanced MRI scans per year, because of their 
high paramagnetic properties, and favorable properties in term of enhancing relaxation 
enhancement, high stability and inert body.  
Clinical MRI contrast agents are mostly small molecular Gd (III) chelates, and they usually 
have high stability. The first MRI contrast agent Gd-DTPA has been permitted to be used in 
clinic in 1988.[31] It was firstly used in detecting the breakage of the blood brain barrier (BBB) 
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in brain tumors. Afterwards, plenty of Gd (III) chetales have been developed to be used in clinic, 
as Figure 1.3 shows. Macromolecular MRI contrast agents are mainly prepared by conjugated 
Gd-DOTA to biocompatible macromolecules. Various bifunctional chelates of DOTA have 
been developed with functional goups such as anhydride, N-hydroxysuccinimide activated 
carboxylic acis, malemide, alkynyl and azide for conjugation. Bifunctional ligands and small 
molecular Gd chelates can be readily attached to many biocompatible macromolecules such as 
proteins, polymers and dendrimers to produce macromolecular contrast agents. Although there 
has been superparamagnetic iron oxide nanoparticles (SPIO) which is approved by FDA for 
human uses, these agents are not positively accepted in the area of radiology, possibly because 
of negative contrast enhancement and their prolonged in vivo contrast enhancement, up to 
several months. Clinical Gd (III) based MRI contrast agents can offer strong positive contrast 
enhanement and metabolite quickly from human body after the MRI examinations.  
Nowadays, Gd (III) based MRI contrast agents have been widely used in clinical practice. 
Targeted delivery of contrast agents into tumor tissues is crucial in cancer diagnostic MRI. 
Tumor is physiologically different from normal tissue and has leaky blood vasculature. Thus, 
nanosized contrast agents can passively accumulate in the tumor via tumor vascular 
permeability to macromolecules [32]. Tumor tissues also express numerous cancer-related 
biomarkers, such as P-selectin, on tumor cell surface, extracellular matrix or angiogenic 
microvessels, which can be targeted for molecular imaging. Abundantly expressed cancer 
biomarkers and ligands with high-binding affinity are essential for designing targeted contrast 
agents in order to generate sufficient contrast enhancement for visualizing these biomarkers 
with contrast enhanced MRI. 
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Figure 1.3 Structures of the Gd(III) based MRI contrast agents currently used in the clinical practice.[29] 
1.6 Relaxivity and safety of Gd (III)-DOTA 
The high relaxation of a contrast agent is vital for effective contrast enhanced MRI. Relaxivity 
of the contrast agent describes its ability to alter the rate of water proton relaxation. Gd (III)-
DOTA contrast agents can increase both T1 and T2 relaxation rates (1/T1,2) of water protons. 
The observed water proton relaxation rates include the contributions from the relaxation rates 
(1/T1,2)d without a contrast agent and the increased relaxation rates (1/T1,2)p by the contrast 
agent. The increased relaxation rates of water protons are linearly related to the concentration 
of the contrast agent within the range of clinically relevant concentrations. The realxivity is 
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defined as the concentration-dependent increase in relaxation rate of water protons by the 
contrast agent in the units of mM-1S-1. 
(1 𝑇𝑇1,2)� 𝑜𝑜𝑜𝑜𝑜𝑜
= (1 𝑇𝑇1,2)� 𝑑𝑑
+ 𝑟𝑟1,2[Gd] �1. 1� 
The relaxivities of traditional small molecular contrast agents can vary if they bind to 
macromolecules such as plasma proteins or some polysaccharide, for example, fucoidan which 
is used in our study. For the contrast agents binding to proteins, the relaxivities can change by 
the concentrations of the agents and plasma proteins [33]. Moreover, the relaxivities are 
dependent on magnetic field strength [34, 35].  
Safety is also a very important element of MRI contrast agent for clinical applications. Gd(III) 
ions cannot be administered directly because of their high toxicity in ionic form, acutely 
interfering with calcium channels and protein binding sites.[36, 37] Free Gd ions accumulate 
in liver, spleen, kidney and bones and have an LD50 = 0.2 mmol/kg in mice.[29] Gd(III) ions 
are complexed with chelating ligands to prevent tissue interaction and minimize toxic side 
effects. The FDA has issued a black box warning to prohibit the use Gd(III) based contrast 
agents in the patients with renal malfunctions. Therefore, Gd(III) chelate based MRI contrast 
agents with good safety profiles should have high thermodynamic and kinetic stability. The 
contrast agents should be excreted after the contrast enhanced MRI within hours of 
administration. 
1.7 Fucoidan 
In this work, P-selectin was chosen as the molecular target. Fucoidan (the typical structures are 
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shown in Figure 1.4) is a sulfated polysaccharide (MW: average 20,000) found mainly in 
brown algae and brown seaweed. Fucoidan is used as an ingredient in some dietary 
supplement products. 
It has been previously demonstrated in vivo by us and other groups, that fucoidan-
functionalized nanoparticles or microparticles targeting P-selectin can be used for the diagnosis 
of endothelial activation and intraluminal thrombosis, and for tumor-selective drug delivery [5, 
38, 39]. Fucoidan refers to a type of highly sulfated polysaccharide containing L-fucose groups 
[40]. This natural compound exhibits a high affinity for P-selectin, mimicking its main ligand 
the P-selectin Glycoprotein Ligand 1 (PSGL-1) [41]. Fucoidan has a nanomolar affinity for the 
P-selectin expressed by activated platelets in the thrombus [8]. We work herein with fucoidan, 
the P-selectin targeting polysaccharide, linking with dextran, using in vivo click reaction, to 
achieve specific detection of PDAC tumor xenografts in mice [42]. 
Figure 1.4 Typical structure of fucoidan (FCSPs) obtained from some brown seaweed species in the 




The aim of this study was to develop multimodality P-selectin-targeted imaging probes using 
fluorescent dye, gadolinium chelates, superparamagnetic iron oxide particles, and natural 
dextrans. In the following sections, we describe the synthesis and characterization of these 
imaging agents. Gadolinium chelates and superparamagnetic iron oxide particles are used for 
T1- and T2*-weighted MRI and dextrans can be directly detected through its abundant 
hydroxyl protons by CEST MRI [9, 44]. Development of P-selectin targeted dextrans for CEST 






2. Experimental Methods 
2.1 Synthesis 
2.1.1 Materials 
Amino-dextran (MW= 500KD), and N, N′-Disuccinimidyl carbonate (MW:256.17, abbr. DSC) 
and Fucoidan (MW: ~150 KD) were purchased from Sigma Aldrich (Saint Louis, MO, USA). 
DBCO-NH2 (MW: 276.3) is acquired from BroadPharm (San Diego, California). NHS-PEG-
Azide (C15H24N4O8 MW: 388.37) is acquired from Thermo Fisher Scientific.  
2.1.2 Synthesis Method of Dextran-N3 
Amino-dextran of 0.3 umol (150 mg) is dissolved in 500 uL PBS pH:7.4~8.0, followed by 
adding 21 umol (8.3mg) NHS-PEG-N3 （dissolved in 500 uL PBS pH:7.4~8.0）.The mixture 
is vortexed and allowed to conjugate for 2 hours at room temperature. Excess reactants are 
removed by dialysis for 1 day. The product is freeze-dried. 
2.1.3 Synthesis Method of Fucoidan-DBCO 
Fucoidan of 100 mg (0.7 umol) is dissolved in DMSO pH:7.4~8.0. Then, N, N′-Disuccinimidyl 
carbonate (abbr. DSC) in DMSO (5.1 mg, or 20 umol) and 10 uL triethylamine (abbr. TEA) are 
slowly added to the solution with pH of 7.4~8.0. The mixture is vortexed and allowed to 
conjugate for 2 hours at room temperature. The product was then purified by acetone 
precipitation followed by centrifugation at 4000 rpm in pellets for about 5~10 mins. All of the 
synthesized Fucoidan-DSC (MW: ~495) is dissolved in 500 uL PBS (pH:7.4~8.0), After that, 
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we added 27 umol (7.46 mg) DBCO-NH2 (dissolved in 500 uL DMSO, PH:7.4~8.0) to the 
solution. The mixture is vortexed and allow to conjugate at room temperature overnight. Excess 
reactants are removed by dialysis for 1 day. The product is freeze-dried. 
Figure 2.1 Scheme of Synthesis Route of (a) Dextran-N3 and (b) Fucoidan-DBCO 
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2.2 In Vitro CEST of Dex10, Dex10-N3, Fucoidan and 
Fucoidan-DBCO 
2.2.1 Preparation of Samples for MR Imaging 
All MRI samples were prepared using 1.5 mL Eppendorf tubes and transferred to 1mm OD 
capillaries for MRI measurement. The solutions at concentration of 1 mg/mL, were prepared 
in 10mM phosphate buffered saline (PBS) buffer and titrated to pH=7.4.  
2.2.2 MRI Measurement and Analysis 
All in vitro MRI datasets were acquired at 37 ℃ (310.15K) on a 400MHz (9.7T) vertical 
scanner (Bruker Biosciences, Billerica, MA) system equipped with a 20mm birdcage RF coil 
using a previously reported protocol [45]. A modified single slice Rapid Acquisition with 
Relaxation Enhancement (RARE) pulse sequence was used to acquire CEST weighted images 
with saturation offset frequencies from -4 ppm to 4 ppm (step = 0.2 ppm) with respect to water 
resonance (set 0 ppm by MRI convention). The imaging parameters were, saturation time (Tsat) 
= 3 s, TR = 10 s, effective TE = 43.2 ms, RARE factor = 32, slice thickness = 2mm, matrix size 
= 64x64, resolution = 0.25x0.25 mm2, and number of averages = 2. The saturation parameters 
were: rectangular RF pulse, saturation time (tsat) = 1,2,3,4 and 6sec and saturation field strength 
(B1) 1.2, 2.4, 3.6, 4.7 and 5.9 μT. The B0 inhomogeneity was corrected using the WASSAR 
method.[46, 47]  
All data were processed using custom-written Matlab scripts. Conventionally, MTRasym is used 
to quantify CEST effect by removing other effects from the acquired Z-spectrum, including the 
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water direct saturation effect and magnetization transfer (MT) effect caused by 
macromolecules, that are assumed to be symmetric with respect to the water resonance [48]. 






Where Δω is the frequency difference of the protons of interest with respect to the water protons 
and S and S0 are the signals acquired with and without saturation, respectively.  
To achieve a linear relationship over a broad concentration range, we also adapted the MTRrex 







To achieve T1 – relaxation time compensated CEST quantification, we used apparent exchange-





Longitudinal (T1) relaxation times of the samples were assessed using a RARE-based 
saturation recovery sequence with eight TR times ranging between 200 ms to 15,000 ms. T1 
relaxation times were estimated by fitting the ROI values to Equation 2.4 using Matlab, 




Where S(TR) are the MRI signal at each TR time, and the theoretical maximal MRI signal S0 
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and T1 time are the parameters to be estimated. 
In addition, transverse (T2) relaxation times were measured using the same RARE sequence 
with a CPMG preparation period inserted before the imaging readout.[50] The inter-echo time 
delay (τCMPG) was fixed at 10 ms and the pulse numbers were varied from 4 to 1024. The 
acquisition time for each T2-weihted image was 25 sec. T2 relaxation times were estimated by 
fitting the ROI values to Equation 2.5 using Matlab,  




Where S(TE) are the MRI signal at each TE time, and the theoretical maximal MRI signal M0 
and T2 time are the parameters to be estimated. 
2.3 Histological Analysis of P-selectin Expression in tumor 
and muscle 
2.3.1. Immunohistochemistry (IHC) Staining Protocol  
Materials: P-selectin Antibody (CTB201): sc-8419 was purchased from Santa Cruz 
Biotechnology. P-Selectin Antibody (CTB201) is a mouse monoclonal IgG1 (kappa light 
chain) provided at 200 µg/ml. 
The slices are taken from refrigerator (-20 ℃), and they should be kept under room temperature 
and in dark place. The slices are washed with PBS to remove the optimum cutting temperature 
medium (OCT) and to allow staining of the tissues. Tissues were permeabilized the tissues with 
acetone, leave to fix the tissue under -20 ℃ for 10 min. Wetting the slices with PBS, circle the 
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tissues with hydrophobic marker. Incubating the tissues for 1h in block (BSA), room 
temperature. It is recommended that as incubations can be very long in whole mount staining, 
the P-selectin antibody should be diluted in blocking buffer (1:200 in BSA). Washing the slices 
with PBS 3X5 min in PBS. Add secondary antibody (Anti-Mouse IgG Alexa Fluor 594) in 
blocking buffer (1:500 in BSA), incubate for 30 min, room temperature. Washing 3X5 min in 
PBS again. Staining the slices with 1:100 DAPI, incubate for 5 min. Wash in PBS. Mount and 
view the slices. Store at 4℃ in the dark until analysis 
Immunohistochemical localization of P-selectin was determined in tumor and muscles samples 
after intravital microscopy was completed. For P-selectin channel, we set the minimum 
intensity was 2640 and the maximum intensity was 56062 to keep the consistent intensity both 
in tumor and in muscle. We assumed that if the intensity we tested in tumor is higher, then we 
can prove that P-selectin over expresses in tumor. 
2.4 Ex Vivo Fluorescence Imaging 
2.4.1 Cell Culture 
The murine PDAC KPC cells[42] were derived from KrasLSL.G12D/+; p53R172H/+; PdxCretg/+ (or 
KPC) mice. KPC cells were cultured at 37 °C and 5% CO2 in RPMI medium supplemented 
with 10%FBS (100ml), 1% PenStrep (10ml), 1% MEMNEAA (10ml), 1% Sodium Pyruvate 
(10ml) and 1% L-glutamine (10%). 
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2.4.2 The KPC Model of Pancreatic Ductal Adenocarcinoma 
We utilized a variety of genetically engineered mouse models of pancreatic cancer. However, 
the principle model utilized in the Mouse Hospital is the KrasLSL.G12D/+; p53R172H/+; PdxCretg/+ 
(or KPC) model, a well-validated, clinically relevant model of PDAC.[51] KPC mice develop 
a spectrum of premalignant lesions called Pancreatic Intraepithelial Neoplasia (PanINs) that 
ultimately progresses to overt carcinoma with 100% penetrance. The tumors generally have a 
moderately differentiated ductal morphology with extensive stromal desmoplasia, similar to 
the most common morphology observed in humans. Metastases are observed in 80% of KPC 
mice, primarily in the liver and lungs, the same sites most commonly observed in humans. The 
tumors exhibit numerous immunohistochemical markers of PDA and harbor complex genomic 
rearrangements indicative of genomic instability. Furthermore, KPC mice develop the co-
morbidities associated with human PDA such as cachexia, jaundice and ascites. Finally, 
pancreatic tumors in KPC mice are predominantly resistant to chemotherapy, with only 12% 
of tumors demonstrating a change in growth kinetics after treatment with gemcitabine.[52] 
2.4.3 Animal Model 
All animal experiments were conducted in compliance to protocols approved by institutional 
Animal Care and Use Committee of Johns Hopkins University. One million KPC cells (in 200 
µL PBS) were subcutaneously injected to both lower flanks of C57BL/6J mice (6–8-week-old 
females, Jackson Laboratories, USA) to form two tumors (for successful tumorigenesis). Mice 





2.5 Relaxivity of Gd(DOTA)-N3 
High relaxivity of a contrast agent is critical for effective contrast enhanced MRI. Relaxivity 
of the contrast agent describe its ability in changing water proton relaxation rates. Gd (III)-
DOTA-N3 contrast agents can increase both T1 and T2 relaxation rates (1/T1,2) of water 
protons.[53] Hydrophilic Gd (III) contrast agents are primarily used clinically for angiography 
as they are restricted to the vascular space and therefore can identify damaged blood 
vessels.[53-55] This concept can be applied to tumor imaging, as most tumors are more perfuse 
than surrounding tissue.  
2.5.1 Chelation Reaction of T1 Agent Gd(DOTA)-N3 
Materials: Azide-mono-amide-DOTA (C₁₉H₃₄N₈O₇·3HCl, MW: 595.9, 100mg) was purchased 
from Macrocyclics, Inc. Gadolinium (III) acetate hydrate (Gd(CH3CO2)3 · xH2O, MW: 334.38, 
25g ) was purchased from Sigma-Aldrich. 
Synthesis Methods: 0.06mol Azide-mono-amide-DOTA and 0.6mol Gadolinium (III) acetate 
hydrate were dissolved in 10mL DI water, adjust PH = 6.5 with 1M NaOH, oil bath (50 ℃) for 
2 days. Purify the product with HPLC. Freeze-drying the purified product. 
HPLC Methods: Analytical reverse-phase HPLC-MS was performed on a Varian Prostar 500 
system (Agilent Technologies, Santa Clara, CA, USA) with a waters (Milford, MA, USA) 
Atlantis C18 column (4.6×250, 5 μm). This system is equipped with a Varian 380 LC ELSD 
system, a Varian 363 fluorescence detector, and a Varain 335 UV-vis detector, and a Varian 
1200L quadrupole MS detector (Agilent Technologies, Santa Clara. CA, USA). Preparative 
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runs were performed on a Waters (Milford, MA, USA) Atlantis C18 column (19× 250, 10μm). 
The mobile phases consisted of Milipore water (A) and HPLC-grade acetonitrile (B). HPLC 
method 1:0-5 min 100% A, 5-24:08 min 57.5% A, 24:08-30 min 0% A, 30-35 min 0% A, 35-
40 min 100% A. 
2.5.2 Chelation of T2 Agent SPIO-N3 
Materials: SPIO-COOH was purchased from Ocean NanoTech. EDC and NH2-PEG-N3 (mw 
= 3000) was purchased from Sigma-Aldrich.  
Synthesis Methods: Equilibrated EDC to room temperature. Prepared 25 mL SPIO-COOH. 
Dissolved 10 mg EDC and 10 mg NHS in 1 mL PBS respectively. Added 10 μL EDC solution 
and 10 μL NHS solution, and mixed with SPIO-COOH in PBS, PH 6.5 and reacted for 30 min. 
Dissolved 25 mg NH2-PEG-N3 in 1 mL PBS, added this solution to the former one and reacted 
for 2 hours, PH 7.4 and room temperature. The product was purified by dialysis. 
2.5.3 T1 and T2 of Gd(DOTA)-N3 
The efficiency of a contrast agent in reducing the longitudinal relaxation time of water protons 
is defined in terms of its relaxivity (mM−1 s−1).[56] It has been predicted by Solomon-
Bloembergen-Morgan theory that slow molecule tumbling of an MR contrast agent will cause 
an increase in rotational correlation time, τr, which in turn results in increased relaxivity.[57] 
One of the common approaches to increasing relaxivity by slowing down the molecular 
tumbling is to attach Gd(III) complexes to a macromolecule through rigid linkages.[58-61] 
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The longitudinal relaxivity (r1) measurements and transverse relaxivity (r2) measurements are 
shown as follows. 
Prepare a series of samples of Gd(DOTA)-N3 at different concentrations, such as 0.39 mM, 
0.19 mM, 0.097 mM, 0.049 mM, 0.024 mM, and measure the T1 and T2 values, respectively. 
Then, plot of C vs 1/T1, and the slop of which will be r1, plot of C vs 1/T2, and the slope of 
which slope will be r2. 
2.6 In Vivo MRI with Azide-Gd(DOTA) 
For in vivo study, the method is shown in Scheme 2. We used an 11.7T Bruker Biospec 
horizontal scanner. T1 and T2 were performed before and after the i.v. injection of 200 uL of 
fucoidan-DBCO and Azide-Gd(DOTA) solutions in saline (500mg/kg b.w.), using the 
following parameters: B1 = 1.8 μT, tsat = 3 s, Δω range of -3 to +3 ppm with a step size of 0.2 
ppm, TR/TE = 5 s/18.6 ms, number of averages = 2, slice number = 1, slice thickness = 1 mm, 
matrix size = 64 × 64, field of view = 25 mm × 25 mm, total scan time = 5 min for 1 image. 
The B0 inhomogeneity maps was acquired before and after the CEST acquisitions using 
MASSR method using the following parameters: B1 = 0.5 μT, tsat = 500 ms, Δω range of -1 to 
+1 ppm with a step size of 0.1 ppm. Equation 2.1 was computed after the B0 correction. 
ΔMTRasym at each time point was calculated by MTRasym(t) - MTRasym(pre). Data were processed using 
custom-written MATLAB programs. T1 maps were acquired using the same geometry and spatial resolution 
as CEST MRI with a RARE-VTR sequence (RARE with variable TRs, effective TE = 25 ms and RARE factor 
= 4) with 12 TR times ranging from 60 ms to 10 s. Total time of T1 mapping is 5min for 1 image. T2 maps 





3.1 Synthesis of Dextran-N3 and Fucoidan-DBCO 
We first conjugated Amino-dextran and NHS-PEG-N3 to construct CEST agent dextran-N3 
according to the route shown in Scheme 1(a). We got Dextran-N3 79.5 mg, and after calculation, 
we got the yield is 53.0%.  
We also successfully synthesized fucoidan-DBCO according to the route shown in Scheme 
1(b). First, we conjugated fucoidan and N, N′-Disuccinimidyl carbonate (abbr. DSC). Briefly, 
N, N′-Disuccinimidyl carbonate (DSC) was used to active the hydroxyl groups of fucoidan to 
form succinimidyl groups. The conjugation of the activated fucoidan was synthesized with 
DBCO-NH2 to form fucoidan-DBCO. We got Fucoidan-DBCO 158.4 mg, and after calculation, 
we got the yield is 58.5%. 
Finally, we characterized dextran, dextran-N3, fucoidan and fucoidan-DBCO using in vitro 
CEST MRI to prove we successfully synthesized dextran-N3 and fucoidan-DBCO. The CEST 
results are shown below. 
3.2 In Vitro CEST Results  
Figure 3.1 is the in vitro MRI result of fucoidan and dextran. We tested the T2 weighted imaging and 
CEST imaging, Using the asymmetric magnetization   transfer ratio Equation 2.1 to get the 
MTRasym values and get the plot. 




Figure 3.3 Quantification of P-selectin Expression in Tumors and Muscles (N=3, two-tailed unpaired 
Student’s test, based on whole-tumor ROI) 
We randomly choose three mice for different groups, and this is the result we got.  
Our preliminary inference is P-selectin expresses more in tumor than which in muscle. 
According to the above Figure 3.2a and Figure 3.2b, we can see the intensity of P-selectin in 
tumor is obviously higher than which in muscle. That means P-selectin expression in tumor is 
much more than which in muscle. 
As is shown in Figure 3.3, we also made quantitative analysis of fluorescence intensity. The 
average fluorescence intensity of P-selectin in tumor and in muscle is about 28 and 2 
respectively, and the P value is 0.0011(<<0.5), therefore, the result is significant, which means 
P-selectin expression in tumor is much more than which in muscle. This result fully explain 




3.4 Ex Vivo Fluorescence Imaging 
we performed preliminary in vivo testing in subQ tumor model to examine Cy5.5-azide 
localization to mice injected with fucoidan-DBCO to see the feasibility of later MR Imaging 
and make dual proof of P-selectin’s over expression in tumor. 
Sulfo-Cyanine5.5 (Figure 3.4) is a water-soluble, hydrophilic fluorophore. As other cyanine 
dyes, ulfo-Cyanine5.5 has an outstanding molar extinction coefficient which gives rise to its 
bright fluorescence. The molecule contains four sulfo groups that provide hydrophilicity and 
negative charge to the fluorophore – this minimizes non-specific binding.  
The subcutaneous tumors were formed by implanting syngeneic KrasLSL.G12D/+; p53R172H/+; 
PdxCretg/+ (KPC)-derived PDAC cells[62]. The implantable model shares similar ECM and 
immunobiology as the parental tumors arising spontaneously in KPC mice, providing a simple 
and well-controlled model that recapitulates cellular and molecular pathology of human 
PDAC[63, 64]. To ensure successful tumor formation, two tumors were implanted on both 
sides of the flank of each mouse subcutaneously (Figure 3.5). 
Figure 3.4 Chemical Structure of Sulfo-Cy5.5-N3 
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Figure 3.5 Schematic of the tumor position 
Our results are shown in Figure 3.6 and Figure 3.7. According to the of fluorescence 
examination results of control group and experimental group (Figure 3.6), we can see the 
difference between tumor and muscle in experimental groups is bigger than which in the control 
groups. That proves the high expression of the P-selectin allows a stronger imaging probe 
accumulation. Biodistribution studies of the fucoidan-based nanoparticles in mice bearing P-
selectin expressing tumors found selective tumor accumulation within 24 hours after injection. 
Apart from the tumors, the organs exhibiting nanoparticle accumulation were the lungs and the 
liver, with virtually no uptake in the spleen. Although nanoparticles often accumulate in the 
liver and spleen, often before hepatobiliary clearance, it was previously found that the use of 
endothelial targets can modulate nanoparticle biodistribution to the lungs, likely due to the 
large endothelial component in this organ[65]. 
Besides, after analyzing ROI values of control groups and treatment groups, we got the P value 
is 0.0484 (<0.05), so we can say the result is significant and this means Fucoidan-DBCO and 





mM-1s-1 after adding fucoidan-DBCO. The increase of r1 relaxivty after adding fucoidan-
DBCO suggest that the binding of Gd(DOTA)-N3 to fucoidan-DBCO decreased the tumbling 
rate of the agents, thereby increasing r1 relaxivty.  
3.5.3 In vivo MRI of PDAC using Gd(DOTA)-N3 
 
Figure 3.10 (a) T1-weighted MRI of PDAC using Gd(DOTA)-N3. (b) Plots of in vivo MRI of tumor 
and muscle 
Gd(DOTA)-N3 was used for in vivo MRI of PDAC with or without pre-targeting using 
fucoidan-DBCO at 11.7T. Mice were i.v. injected with 50 mg/kg fucoidan-DBCO. After 1 h, 
Gd(DOTA)-N3 was i.v. injected at the dose of 0.2 mmol/kg, during which pre-injection images 
(pre) and post-injection images up to 1 h were acquired using T1-weighted MRI and T1 
mapping. It was shown that mice with fucoidan-DBCO injection demonstrated higher tumor 
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signal increase in tumor at later times (after 20 min), as revealed by post-pre images and ∆R1 
values (N=2). Although we have not acquired sufficient replicates for each group, this data 
demonstrated the superior tumor enhancement using our platform. More studies would be done 





This study aimed for develop versatile platform for multimodality of pancreatic cancer by 
targeting P-selectin. P-selectin was chosen as a biomarker which is highly overexpressed in the 
microenvironment of pancreatic tumors[42, 66]. Tumor vasculature, which is composed of 
smooth muscle cells, pericytes, extracellular matrix, and endothelial cells (ECs), is necessary 
for the growth and support of tumors. The EC component of tumor neovasculature is a 
promising target for antitumor therapy because of its genetic stability, exposure to the 
circulation, and direct access from intravascular space[67]. P-selectin, an inflammatory cell 
adhesion molecule responsible for leukocyte recruitment and platelet binding[68-71], is 
expressed constitutively in ECs. It has been found that many human tumors express P-selectin 
on tumor cells and in tumor vasculature. We found only several reports describing the role of 
P-selectin as a target for cancer detection and drug delivery[5]. Because of the high prevalence 
of P-selectin in the microenvironments of human tumors and metastases, as evinced by IHC 
staining, we surmised that targeting P-selectin may improve early detection of Pancreatic 
cancer (PDAC). 
In this study, we have functionalized fucoidan for in vivo click reaction with imaging moieties 
to achieve specific detection of PDAC tumor xenografts in mice. We chelated T1 contrast agent 
Gd(DOTA)-N3 and T2 contrast agents SPIO-N3, and synthesized CEST agent dextran-N3. We 
measured relaxivities of Gd(DOTA)-N3 in vitro and in vivo and get its contrast enhancement 
in PDAC tumors. Also, we performed ex vivo fluorescence localization detection to dual prove 
over expression of P-selectin in tumors and verify the feasibility of later in vivo MR Imaging 
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to detect PDAC tumor in mice.  
In conclusion, in this study, we developed several image probes to bind with fucoidan targeting 
P-selectin for early detection of pancreatic cancer. Our ultimate goal is to design a new MRI 
probe for targeted imaging of tumor microenvironment biomarker P-selectin in a murine PDAC 
model, and this new probe consists of diamagnetic and biocompatible dextran and the high 
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Master of Engineering in Chemical and Biomolecular Engineering  
Zhejiang University                  09/2012-07/2016 
Bachelor of Science in Chemistry 
 
PUBLICATIONS & CONFERENCE 
1. J. Zhang, Z. Han, J. Lu, Y. Li, X. Liao, PCM van Zijl, X Yang, G Liu. Triazoles as T2-
exchange MRI contrast agents for the detection of nitrilase activity, Chem. Eur. J., 24, 15013-
15018. 2018 
2. J. Lu, Z. Han, J.Zhang, Y. Li , J. Liu , K. Fujiwara , P. van Zijl , L. Zhang , and G. Liu. 
Dextran-based CEST MRI for detecting extradomain-B fibronectin in pancreatic cancer. 
ISMRM 2019 in Montreal, QC, Canada. 
 
RESEARCH EXPERIENCE 
Johns Hopkins University                                                        
A Versatile Platform for Multimodality Imaging of Pancreatic Tumor by Targeting P-
selectin             
Advisor: Guanshu Liu, PhD           07/2018-Present 
Aims: Develop targeted dextran polymers as MR molecular imaging agents for early detection 
of pancreatic cancer (PDAC). Dextran polymers are highly biocompatible diamagnetic agent, 
the abundant hydroxyl protons of which are detectable in chemical exchange saturation transfer 
(CEST) MRI. Dextran polymers were linked to fucoidan, a P-selectin targeting polysaccharide, 
using in vivo click reaction, to achieve specific detection of PDAC tumor xenografts in mice.   
• Synthesized fucoidan-DBCO and dextran-azide for in vivo click reaction.  
• Evaluated the CEST signal of fucoidan-DBCO and dextran-azide in Bruker 400MHz 
vertical scanner. 
• Performed preliminary in vivo testing in subQ tumor model derived from KrasLSL.G12D/+; 
p53R172H/+; PdxCretg/+ (KPC). Examined localization of Cy5.5-azide localization to mice 
injected with fuoidan-DBCO by ex vivo fluorescence imaging 
Triazoles as T2-Exchange MRI Contrast Agents for the Detection of Nitrilase Activity 
Advisor: Guanshu Liu, PhD           09/2017-05/2018 
Aims: Develop triazoles as sensitive and tunable diagnostic T2-exchange agents in MRI. 
• Characterized the T2-exchange (T2ex) MRI contrast of azole protons that have large 
chemical shifts from the water proton resonance as a function of pH, temperature, and 
chemical modification. 
• Studied exchange rates using the Swift-Connick equation to optimize the T2ex effect. 
• Applied T2-exchange MRI to assess the activity of nitrilase, an enzyme catalyzing the 
hydrolysis of 1,2,4-triazole-3-carbonitrile to 1,2,4-triazole-3-carboxylic acid, resulting 
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in the enhancement of R2ex. 
Technical Institute of Physics & Chemistry, Chinese Academy of Sciences             
Features and Disbanding of Hydrogen Bands of Cellulose Chains 
Advisor: Yong Huang, PhD                    09/2016 
• Researched on the reconstruction process and control factors of hydrogen bonding 
between the hydroxyl groups on cellulose macromolecular chains. 
• Explored the relationship between the reconstruction of the hydrogen bond and the 
properties of cellulose macromolecules.  
• Investigated the effects of small molecules on cellulose intermolecular and 
intramolecular hydrogen bond by FTIR, NMR, DSC and QCM. 
Structure and Responsibility of Dual-stimuli Sensitive Cellulose Based Graft Copolymers 
Advisor: Yong Huang, PhD                 01/2015-03/2015 
• Synthesized the HPC-g-PDPAEMA graft copolymers with well-defined structure 
through the atom transfer radical polymerization (ATRP). 
• Tested the copolymer’s dual sensitivity of pH and temperature in aqueous solution. 
 
Zhejiang University                                                                                                                      
Diversity Oriented Synthesis Based on Natural Phenolic Compound 
Advisor: Jun Wu, PhD   Undergraduate Thesis      12/2015-06/2016 
• Consulted relevant documents and materials and then wrote the literature translation, 
literature review and research proposals. 
• Synthesized salicylaldehyde with 8 different kinds of aromatic amines and aliphatic 
amines material. 
• Recrystallized the products and separated the products with column chromatography 
• Characterized the structure of the products by nuclear magnetic resonance and tested 
the biological activity of the products. 
• Analyzed experimental data, wrote a thesis and finally completed thesis defense. 
 
TECHNICAL SKILLS                                                
Experimental Skills: proficient in a variety of chemical experimental instruments and 
measuring methods such as IR, UV, NMR, FTIR, NMR, DSC, QCM, and MRI 
Proficient in Origin, Nova, Chemdraw, TopSpin, GraphPadPrism, Endnote, C Language 
